- Ark Invest‘s Q3 portfolio report highlighted strong returns from its blockchain and AI-focused ETFs, led by Palantir.
- Biotech holding 10x Genomics surged on demand for AI-driven drug discovery data.
- Tesla and Rocket Lab acted as the most notable drags on portfolio performance.
- NVIDIA was among the other contributors to the technology-focused funds.
Cathie Wood-led Ark Invest released its Q3 portfolio report, highlighting how AI and crypto-adjacent tech bets drove strong gains across its ETFs.
Palantir emerged as a top cross-fund contributor, adding 2.39 percentage points to the ARK Blockchain & Fintech Innovation ETF (ARKF). Meanwhile, 10x Genomics was the standout overall, contributing 9.03 points to the Genomic Revolution ETF on AI drug-discovery demand.
Twist Bioscience and Nvidia also made meaningful contributions to the technology and biotech funds. Conversely, Tesla was the biggest drag across multiple Ark portfolios following profitability disappointments.
Rocket Lab similarly weighed on space-focused ETFs despite a busy launch schedule. For ongoing analysis of these disruptive-tech trends, follow related coverage on Google News.
✅ Follow BITNEWSBOT on Telegram, Facebook, LinkedIn, X.com, and Google News for instant updates.
